Post-marketing liver safety data from 4 years of the tolvaptan risk evaluation and mitigation strategy (rems) in the treatment of autosomal dominant polycystic kidney disease (adpkd)
AMERICAN JOURNAL OF KIDNEY DISEASES(2023)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要